Bristol-Myers Squibb Company (ETR:BRM)
Germany · Delayed Price · Currency is EUR 40.16
-0.83 (-2.01%)
Sep 12, 2025, 5:35 PM CET
ETR:BRM Revenue
Bristol-Myers Squibb Company had revenue of $12.27B USD in the quarter ending June 30, 2025, with 0.56% growth. This brings the company's revenue in the last twelve months to $47.70B, up 2.57% year-over-year. In the year 2024, Bristol-Myers Squibb Company had annual revenue of $48.30B with 7.32% growth.
Revenue (ttm)
$47.70B
Revenue Growth
+2.57%
P/S Ratio
1.98
Revenue / Employee
$1.40M
Employees
34,100
Market Cap
80.24B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 48.30B | 3.29B | 7.32% |
| Dec 31, 2023 | 45.01B | -1.15B | -2.50% |
| Dec 31, 2022 | 46.16B | -226.00M | -0.49% |
| Dec 31, 2021 | 46.39B | 3.87B | 9.09% |
| Dec 31, 2020 | 42.52B | 16.37B | 62.62% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Siemens Healthineers AG | 23.38B |
| Merck KGaA | 21.22B |
| Bayer Aktiengesellschaft | 46.17B |
| Fresenius SE & Co. KGaA | 22.28B |
| Fresenius Medical Care AG | 19.52B |
| Sartorius Aktiengesellschaft | 3.47B |
| Fielmann Group AG | 2.40B |
| Carl Zeiss Meditec AG | 2.18B |
Bristol-Myers Squibb Company News
- 5 days ago - Bristol-Myers Squibb (BMY) Advances in Small Cell Lung Cancer Treatment - GuruFocus
- 5 days ago - BioNTech, Bristol Myers Squibb Show Tumor Shrinkage In Lung Cancer Immunotherapy - Benzinga
- 5 days ago - First Disclosure of Global Interim Phase 2 Data for BioNTech and Bristol Myers Squibb ... - GuruFocus
- 5 days ago - Bristol-Myers Squibb Company (BMY) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript) - Seeking Alpha
- 5 days ago - Bristol-Myers Squibb: Why Q2 Results Signal A Turning Point - Seeking Alpha
- 6 days ago - Bristol-Myers Squibb: Growth Portfolio Surpasses Legacy, Driving Oncology And Immunology Leadership - Seeking Alpha
- 7 days ago - Insider trades: Nvidia, Bristol Myers Squibb, Gamestop among notable names this week - Seeking Alpha
- 7 days ago - Bristol Myers Squibb: A 5% Yield And Single-Digit P/E Still Look Good - Seeking Alpha